文献速递中毒与环境急症消化、代谢与肾脏急症

成人可卡因使用障碍治疗方法比较:系统评价与Meta分析

Comparison of Treatments for Cocaine Use Disorder Among Adults: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Netw Open · 2021-05-03
一句话结论在157项试验、15842例受试者中,仅 contingency management 项目与可卡因尿检阴性率提高显著相关(OR 2.13,95%CI 1.62-2.80)。

该系统评价与Meta分析检索PubMed和Cochrane系统评价数据库,纳入1995年12月31日至2017年12月31日发表的157项临床试验(402个治疗组、15842例患者),比较成人活动性可卡因使用障碍的11类治疗。主要终点为治疗期末可卡因代谢物尿检阴性的意向性治疗对数OR(与基线比较)。仅 contingency management 项目与尿检阴性可能性增加显著相关(OR 2.13,95%CI 1.62-2.80),且在所有敏感性分析中均保持显著。作者认为,与该治疗模式一致的研究和政策可能使活动性可卡因使用者获益并减轻社会负担。

要点

  • 纳入157项研究、402个治疗组、15842例活动性可卡因使用的成人门诊患者。
  • 仅 contingency management 项目与可卡因尿检阴性率提高显著相关(OR 2.13,95%CI 1.62-2.80)。
  • 该关联在所有敏感性分析中均保持显著。
  • 除其他治疗外,样本量最大的治疗组为心理治疗(均值[SD] 40.04[36.88]例)和 contingency management 项目(37.51[25.51]例)。
  • 作者认为,与该治疗模式一致的研究和政策可能使活动性可卡因使用者获益并减轻社会负担。

适用人群与场景

  • 门诊患者,年龄18岁及以上,基线时有活动性可卡因使用。
  • 排除:超过25%的参与者不是活动性可卡因使用者,或超过80%的参与者在基线时可卡因代谢物检测结果为阴性。
  • 排除:仅报告提示多种物质存在的合并尿检结果,且未报告可卡因代谢物阳性检测结果的具体比例。

诊断标准与关键阈值

  • 纳入标准:文章标题含cocaine一词;1995年12月31日至2017年12月31日发表;英文撰写;纳入18岁及以上基线有活动性可卡因使用的门诊患者;报告治疗组大小、治疗时长、保留率和可卡因代谢物尿检结果。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析,检索PubMed和Cochrane系统评价数据库,检索1995年12月31日至2017年12月31日发表的临床试验。
  • 共筛查831条记录,157项研究(18.9%)符合选择标准并纳入分析,共402个治疗组、15842例参与者。
  • 治疗分为11类:心理治疗、contingency management 项目、安慰剂、阿片类药物、精神兴奋剂、抗惊厥药、多巴胺激动剂、抗抑郁药、抗精神病药、其他药物和其他治疗。
  • 主要终点:治疗期末可卡因代谢物尿检阴性的意向性治疗对数OR(与基线比较)。
  • 仅 contingency management 项目与可卡因尿检阴性可能性增加显著相关(OR 2.13,95%CI 1.62-2.80),且在所有敏感性分析中均保持显著。
  • 除其他治疗外,所有研究中样本量最大的治疗组为心理治疗(均值[SD] 40.04[36.88]例)和 contingency management 项目(37.51[25.51]例)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,遵循PRISMA指南,在Covidence.org注册(研究8731)。
  • 数据分析采用多水平随机效应模型、多水平混合效应Meta回归模型和敏感性分析,缺失数据用链式方程多重插补,显著性阈值P = .05。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与该治疗模式一致的研究和政策可能使活动性可卡因使用者获益并减轻社会负担。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: In the US and the United Kingdom, cocaine use is the second leading cause of illicit drug overdose death. Psychosocial treatments for cocaine use disorder are limited, and no pharmacotherapy is approved for use in the US or Europe.

OBJECTIVE: To compare treatments for active cocaine use among adults.

DATA SOURCES: PubMed and the Cochrane Database of Systematic Reviews were searched for clinical trials published between December 31, 1995, and December 31, 2017.

STUDY SELECTION: This meta-analysis was registered on Covidence.org (study 8731) on December 31, 2015. Clinical trials were included if they (1) had the term cocaine in the article title; (2) were published between December 31, 1995, and December 31, 2017; (3) were written in English; (4) enrolled outpatients 18 years or older with active cocaine use at baseline; and (5) reported treatment group size, treatment duration, retention rates, and urinalysis results for the presence of cocaine metabolites. A study was excluded if (1) more than 25% of participants were not active cocaine users or more than 80% of participants had negative test results for the presence of cocaine metabolites at baseline and (2) it reported only pooled urinalysis results indicating the presence of multiple substances and did not report the specific proportion of positive test results for cocaine metabolites. Multiple reviewers reached criteria consensus. Of 831 records screened, 157 studies (18.9%) met selection criteria and were included in the analysis.

DATA EXTRACTION AND SYNTHESIS: This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline. Search results were imported from PubMed XML into Covidence.org then Microsoft Excel. Data extraction was completed in 2 iterations to ensure fidelity. Analyses included a multilevel random-effects model, a multilevel mixed-effects meta-regression model, and sensitivity analyses. Treatments were clustered into 11 categories (psychotherapy, contingency management programs, placebo, opioids, psychostimulants, anticonvulsants, dopamine agonists, antidepressants, antipsychotics, miscellaneous medications, and other therapies). Missing data were imputed using multiple imputation by chained equations. The significance threshold for all analyses was P = .05. Data were analyzed using the metafor and mice packages in R software, version 3.3.2 (R Foundation for Statistical Computing). Data were analyzed from January 1, 2018, to February 28, 2021.

MAIN OUTCOMES AND MEASURES: The primary outcome was the intention-to-treat logarithm of the odds ratio (OR) of having a negative urinalysis result for the presence of cocaine metabolites at the end of each treatment period compared with baseline. The hypothesis, which was formulated after data collection, was that no treatment category would have a significant association with objective reductions in cocaine use.

RESULTS: A total of 157 studies comprising 402 treatment groups and 15 842 participants were included. Excluding other therapies, the largest treatment groups across all studies were psychotherapy (mean [SD] number of participants, 40.04 [36.88]) and contingency management programs (mean [SD] number of participants, 37.51 [25.51]). Only contingency management programs were significantly associated with an increased likelihood of having a negative test result for the presence of cocaine (OR, 2.13; 95% CI, 1.62-2.80), and this association remained significant in all sensitivity analyses.

CONCLUSIONS AND RELEVANCE: In this meta-analysis, contingency management programs were associated with reductions in cocaine use among adults. Research efforts and policies that align with this treatment modality may benefit those who actively use cocaine and attenuate societal burdens.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Bentzley BS, Han SS, Neuner S, et al. Comparison of Treatments for Cocaine Use Disorder Among Adults: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021. PMID: 33961037. doi:10.1001/jamanetworkopen.2021.8049

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。